Meeting
2017 ASCO Annual Meeting
A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.
Authors
Safi Shahda
Indiana University, Indianapolis, IN
Safi Shahda , Anne M. Noonan , Tanios S. Bekaii-Saab , Bert H. O'Neil , Amikar Sehdev , Walid Labib Shaib , Paul R. Helft , Patrick J. Loehrer Sr., Yan Tong , Ziyue Liu , Bassel F. El-Rayes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT02375672
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3541)
DOI
10.1200/JCO.2017.35.15_suppl.3541
Abstract #
3541
Poster Bd #
164
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line lenvatinib plus pembrolizumab plus chemotherapy versus chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma (LEAP-015): Safety run-in results.
First Author: Patricio Eduardo Yanez
Poster
2022 ASCO Annual Meeting
Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab as first-line treatment in patients with advanced colorectal cancer RAS/BRAF mutated (mut): NIVACOR trial (GOIRC-03-2018).
First Author: Angela Damato
Poster
2022 ASCO Annual Meeting
A phase II study of perioperative mFOLFOX plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ) and stomach.
First Author: Weijing Sun
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase II study of perioperative mFOLFOX chemotherapy plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ), and stomach.
First Author: Weijing Sun